Stanover 10

Orals

Stanover 10

Stanover 10 is a pharmaceutical tablet formulation of Stanozolol at 10 milligrams per tablet. Stanozolol is a synthetic anabolic steroid derived from dihydrotestosterone (DHT), distinguished by its pyrazole ring modification at the A-ring, which produces a compound with a uniquely high anabolic-to-androgenic ratio and complete resistance to aromatization. Originally developed in 1962, stanozolol has established clinical applications in hereditary angioedema prophylaxis and aplastic anemia management.

Structural Profile

Stanozolol is structurally a 17-alpha methyl, 17-beta hydroxy derivative of DHT with a fused pyrazole ring at the A-ring position. The pyrazole modification substantially increases AR binding affinity compared to parent DHT while eliminating aromatase substrate activity entirely — stanozolol cannot be converted to any estrogenic compound under any physiological conditions. The anabolic-to-androgenic ratio is approximately 320:30 (vs testosterone 100:100), making it one of the most anabolically selective oral compounds.

Pharmacokinetic Profile

Oral stanozolol is absorbed from the gastrointestinal tract with approximately 85–90% bioavailability. Peak plasma concentrations are reached within 1–2 hours. The elimination half-life of the oral form is approximately 9 hours, shorter than the injectable aqueous suspension (~24 hours) due to differences in absorption kinetics. Hepatic metabolism generates multiple metabolites, with the principal urinary metabolites being 3-hydroxystanozolol and 4-beta-hydroxystanozolol, detectable in urine for several weeks post-administration.

Mechanism of Action

Stanozolol binds the androgen receptor with high affinity, driving protein synthesis upregulation, nitrogen retention, and enhanced erythropoiesis through EPO-independent mechanisms. Uniquely, stanozolol binds to sex hormone-binding globulin (SHBG) with high affinity, displacing testosterone and other androgens from SHBG binding sites and thereby increasing the free fraction of co-administered androgens. This SHBG-displacement effect is pharmacologically significant and partially accounts for stanozolol's synergistic effects when used alongside other anabolic compounds.

Formulation

Each Stanover 10 tablet contains 10 mg Stanozolol USP as active ingredient. Excipients include microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and magnesium stearate. Manufactured to USP specification under GMP-compliant conditions. Each batch undergoes complete HPLC concentration and purity testing, dissolution profiling, and microbiological limit testing before release.

Quality Assurance

Every batch of Stanover 10 produced by Biomedica undergoes the complete pharmaceutical release testing protocol before distribution. This includes HPLC compound identity confirmation and purity analysis (specification: ≥98%), concentration verification (specification: ±5% of label claim), sterility testing per USP <71>, bacterial endotoxin quantification by LAL assay (specification: <0.25 EU/mL), and particulate matter inspection per USP <788>. A Certificate of Analysis is issued for every production lot.

Authentication

Each unit of Stanover 10 carries a unique authentication code on its outer packaging. This code can be verified instantly on our Authentication page to confirm the product is genuine Biomedica stock.